

Amarin Corporation plc Investor Relations Department 2 Pembroke House, Upper Pembroke Street 28-32 Duiblin 2 Ireland

Visit IR website ☐ Sign-up for Email alerts ☐ ☐

NASDAQ: AMRN	
Last Trade:	2.85
Trade Time:	12:49 PM ET Apr 26, 2018
Change:	0.17 <b>†</b> (+6.157%)
Day Range	2.72 - 2.85
52-Week Range	2.66 - 4.60
Volume	2,640,710

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

# **Company Profile**

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... (more)

### **Stock Performance**



### Press Releases [View all ]

#### Apr 26, 2018

Amarin To Report First Quarter 2018 Results and Host Conference Call On May 2, 2018

#### Apr 23, 2018

Amarin Announces Promotion of Aaron Berg to Position of Chief Commercial Officer

### Apr 12, 2018

Amarin Sponsors Three Scientific

Presentations Scheduled for National Lipid

Association Scientific Sessions

#### Apr 12, 2018

Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin-Treated Patients with Reduced Kidney Function and Persistent High Triglycerides

### Apr 4, 2018

Amarin Updates First Quarter Revenue
Guidance, Reiterates Full Year Guidance and
Updates on REDUCE-IT Cardiovascular
Outcomes Study Progress and Vascepa®
Promotion Initiatives

# Upcoming Events [View all]

May 2, 2018 7:30 AM

Amarin Q1 Results Conference Call

# Financials [View all]

Fourth Quarter Financial Results

Feb 27, 2018

Annual Report (10-K)

Apr 20, 2018

Proxy Statement (DEF 14A)

Nov 1, 2017

Quarterly Report (10-Q)

Aug 2, 2017

Quarterly Report (10-Q)

May 3, 2017

Quarterly Report (10-Q)